BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 29469959)

  • 21. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
    Cheng L; Wang H; Li S; Liu Z; Wang C
    Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
    Arolt C; Dugan M; Wild R; Richartz V; Holz B; Scheel AH; Brägelmann J; Wagener-Ryczek S; Merkelbach-Bruse S; Wolf J; Buettner R; Catanzariti L; Scheffler M; Hillmer AM
    J Thorac Oncol; 2023 Nov; 18(11):1550-1567. PubMed ID: 37473958
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Stuchi LP; Castanhole-Nunes MMU; Maniezzo-Stuchi N; Biselli-Chicote PM; Henrique T; Padovani Neto JA; de-Santi Neto D; Girol AP; Pavarino EC; Goloni-Bertollo EM
    Genes (Basel); 2020 Aug; 11(9):. PubMed ID: 32824922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.
    Goldstein LD; Lee J; Gnad F; Klijn C; Schaub A; Reeder J; Daemen A; Bakalarski CE; Holcomb T; Shames DS; Hartmaier RJ; Chmielecki J; Seshagiri S; Gentleman R; Stokoe D
    Cell Rep; 2016 Sep; 16(10):2605-2617. PubMed ID: 27568559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
    Haque E; Śmiech M; Łuczyńska K; Bouchard MF; Viger R; Kono H; Pierzchała M; Taniguchi H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
    Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
    Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2.
    Cloer EW; Siesser PF; Cousins EM; Goldfarb D; Mowrey DD; Harrison JS; Weir SJ; Dokholyan NV; Major MB
    Mol Cell Biol; 2018 Nov; 38(22):. PubMed ID: 30126895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Miconazole Contributes to NRF2 Activation by Noncanonical P62-KEAP1 Pathway in Bladder Cancer Cells.
    Tsai TF; Chen PC; Lin YC; Chou KY; Chen HE; Ho CY; Lin JF; Hwang TI
    Drug Des Devel Ther; 2020; 14():1209-1218. PubMed ID: 32273683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
    Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
    Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
    Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
    Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
    Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of deficiency of Kelch-like ECH-associated protein 1 on skeletal organization: a mechanism for diminished nuclear factor of activated T cells cytoplasmic 1 during osteoclastogenesis.
    Sakai E; Morita M; Ohuchi M; Kido MA; Fukuma Y; Nishishita K; Okamoto K; Itoh K; Yamamoto M; Tsukuba T
    FASEB J; 2017 Sep; 31(9):4011-4022. PubMed ID: 28515152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma.
    Li QK; Singh A; Biswal S; Askin F; Gabrielson E
    J Hum Genet; 2011 Mar; 56(3):230-4. PubMed ID: 21248763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare and common genetic variations in the Keap1/Nrf2 antioxidant response pathway impact thyroglobulin gene expression and circulating levels, respectively.
    Matana A; Ziros PG; Chartoumpekis DV; Renaud CO; Polašek O; Hayward C; Zemunik T; Sykiotis GP
    Biochem Pharmacol; 2020 Mar; 173():113605. PubMed ID: 31421134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic modifications but not genetic polymorphisms regulate KEAP1 expression in colorectal cancer.
    Gao L; Yuan F; Che G; Xiao X; Nie X; Wang Y; Jia J; Kong AN; Zhang L
    J Cell Biochem; 2019 Aug; 120(8):12311-12320. PubMed ID: 30825237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of human Keap1 S53 and S293 residues in modulating the binding of Keap1 to Nrf2.
    Wei S; Pei Y; Wang Y; Guan H; Huang Y; Xing T; Johnson RW; Wang D
    Biochimie; 2019 Mar; 158():73-81. PubMed ID: 30576774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
    Hayes JD; McMahon M
    Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
    Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
    J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.